Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02044874 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 603
- Enrollment target
NCT02044874 is a Phase 2 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 603 participants.
The verdict
NCT02044874, a Phase 2 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 603 participants
- Enrollment target
Study Summary
In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.
Interventions
- DRUG Placebo
- DRUG APD356-lorcaserin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02044874
The ClinicalTrials.gov registry entry for NCT02044874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 603 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02044874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02044874 about?
NCT02044874 is a clinical study titled "A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation". In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.
What is the current status of trial NCT02044874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 603 participants. The study started on 2014-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02044874?
The interventions under investigation include: Placebo (DRUG), APD356-lorcaserin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02044874?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.